Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- Outline & objectives
- Definitions
- Spatial distribution of MDR-TB or RR-TB
- MDR/RR-TB in 2020
- Aims of TB treatment
- What’s new in TB treatment
- Current treatment landscape for tuberculosis
- Treatment of isoniazid monoresistant TB
- Treatment principles & strategies
- Changes in classification
- Lancet MDR-TB IPD - meta-analysis
- New kid on the block
- Nix-TB & BPaL
- Pretomanid - Nix-TB
- Nix-TB trial: Primary efficacy analysis
- Nix and linezolid: Outcomes & TEAEs
- Principles of DR-TB treatment design
- The evidence
- PICO questions: Which agents are better?
- Treatment failure, relapse and death rate
- How many drugs to have in the regimen?
- Is treatment routinely stopped?
- Drug resistance and DST
- Drug resistance and DST
- BDQ & DLM in combo?
- Dosing
- Latest WHO categorisation of anti-TB drugs
- Longer or “conventional” MDR-TB regimens
- Shorter MDR-TB regimen
- DR-TB treatment guidelines 2020
- Drugs & regimen pipeline
- Further developments in 2021-23
- Global TB network consilium
- Conclusion
- Thank you
- Affiliations
Topics Covered
- Update on the global situation
- MDR-TB in 2020
- How MDR-TB is currently managed
- Treatment principles and strategies
- Latest WHO categorization of anti-MDR-TB drugs
- Further developments
- Global TB network
Links
Series:
Categories:
Therapeutic Areas:
External Links
- WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
- WHO consolidated guidelines on drug-resistant tuberculosis treatment
- Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
- WHO treatment guidelines for drug resistant tuberculosis: 2016 update
- WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
- The 2020 tuberculosis treatment pipeline Report
- Clinical advice service: the Global Tuberculosis Consilium
Talk Citation
Tiberi, S. (2021, November 28). Multidrug resistant tuberculosis (MDR-TB): an update [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 10, 2024, from https://doi.org/10.69645/TPCP2434.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Simon Tiberi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Simon Tiberi, I'm an infectious diseases consultant
working at Barts Health, the Royal London Hospital and Queen Mary, University of London.
I'm going to talk to you about drug-resistant TB, global situation and management,
and give you an update of what's new in this field.
0:22
Briefly, I would like to outline some of our objectives for today.
I'm going to be talking about the drug resistant TB treatment strategies and principles.
I'll give you the latest WHO categorisation of anti drug-resistant TB drugs.
We will go through the steps of building a drug-resistant TB treatment regimen together,
and we will discuss Consilia, an advisory service for challenging cases.
0:47
First, some definitions.
The first definitions we use are abbreviations.
HR means isoniazid resistance, RR means rifampicin resistance,
MDR-TB is multi-drug resistant TB, which is TB that is resistant to isoniazid and rifampicin.
Pre-XDR TB is a new definition meaning pre-extensively drug-resistant TB
- which has just been released by the World Health Organization in October 2020 -
and that means resistance to isoniazid, rifampicin, and a later-generation fluoroquinolone.
Now there's a new definition of extensively drug-resistant TB,
previously it was isoniazid and rifampicin resistance,
together with a later-generation fluoroquinolone and a second-line injectable aminoglycoside,
now the second-line injectable aminoglycoside has been replaced by either linezolid or bedaquiline.
These are new definitions, because the landscape and the way we treat drug-resistant TB has now changed.